{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:40Z","timestamp":1760028940234},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s40266-013-0075-y","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T06:52:54Z","timestamp":1366095174000},"page":"513-525","source":"Crossref","is-referenced-by-count":12,"title":["Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly"],"prefix":"10.1007","volume":"30","author":[{"given":"Kelechi C.","family":"Ogbonna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"75_CR1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","volume":"48","author":"V Fuster","year":"2006","unstructured":"Fuster V, Ryden LE, Cannom DS, et al. ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation\u2014executive summary: a report of the American College of Cardiology\/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2006;48:854\u2013906.","journal-title":"J Am Coll Cardiol"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","volume":"56","author":"R Marinigh","year":"2010","unstructured":"Marinigh R, Lip G, Fiotti N, Giansante C, Lane D. Age as a risk factor for stroke in atrial fibrillation patients. J Am Coll Cardiol. 2010;56:827\u201337.","journal-title":"J Am Coll Cardiol"},{"key":"75_CR4","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","volume":"327","author":"M Ezekowitz","year":"1992","unstructured":"Ezekowitz M, Bridgers S, James K, et al. VA co-operative study of warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406\u201312.","journal-title":"N Engl J Med"},{"issue":"6","key":"75_CR5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jacc.2003.11.028","volume":"43","author":"SG Rockson","year":"2004","unstructured":"Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. Am Coll Cardiol. 2004;43(6):929\u201335.","journal-title":"Am Coll Cardiol"},{"issue":"6","key":"75_CR6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.amjmed.2009.12.013","volume":"123","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484\u20138.","journal-title":"Am J Med"},{"issue":"2 suppl","key":"75_CR7","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","volume":"141","author":"GH Guyatt","year":"2012","unstructured":"Guyatt GH, Akl E, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombus, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):7S\u201347S.","journal-title":"Chest"},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","volume":"323","author":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","unstructured":"The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505\u201311.","journal-title":"N Engl J Med"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","author":"The Stroke Prevention in Atrial Fibrillation Investigators","year":"1991","unstructured":"The Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527\u201339.","journal-title":"Circulation"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","volume":"18","author":"S Connolly","year":"1991","unstructured":"Connolly S, Laupacis A, Gent M. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"1","author":"P Petersen","year":"1989","unstructured":"Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: The Copenhagen AFSAK study. Lancet. 1989;1:175\u20139.","journal-title":"Lancet"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","author":"Atrial Fibrillation Investigators","year":"1994","unstructured":"Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449\u201357.","journal-title":"Arch Intern Med"},{"issue":"20","key":"75_CR13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","volume":"118","author":"SJ Connolly","year":"2008","unstructured":"Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029\u201337.","journal-title":"Circulation"},{"issue":"3","key":"75_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archinte.1995.00430030071008","volume":"155","author":"D McCrory","year":"1995","unstructured":"McCrory D, Matchar D, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155(3):277\u201381.","journal-title":"Arch Intern Med"},{"issue":"1","key":"75_CR15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/14779072.6.1.57","volume":"6","author":"KW Phillips","year":"2008","unstructured":"Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008;6(1):57\u201370.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(01)01587-X","volume":"38","author":"V Fuster","year":"2001","unstructured":"Fuster V, Ryden LE, Asinger RW, et al. ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2001;38:1231\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"75_CR17","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/archinte.161.20.2458","volume":"161","author":"D McCormick","year":"2001","unstructured":"McCormick D, Gurwitz J, Goldberg R, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161(20):2458\u201363.","journal-title":"Arch Intern Med"},{"issue":"8","key":"75_CR18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/j.1532-5415.2010.02967.x","volume":"58","author":"SL Aspinall","year":"2010","unstructured":"Aspinall SL, Zhao X, Handler SM, et al. The quality of warfarin prescribing and monitoring in Veteran Affairs Nursing homes. J Am Geriatr Soc. 2010;58(8):1475\u201380.","journal-title":"J Am Geriatr Soc"},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2296-12-88","volume":"12","author":"S Young","year":"2011","unstructured":"Young S, Bishop L, Twells L, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"75_CR20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"A Mangoni","year":"2004","unstructured":"Mangoni A, Jackson S. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"75_CR21","volume-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","author":"L Brunton","year":"2011","unstructured":"Brunton L, Chabner B, Knollmann B. Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics. 12th ed. New York: The McGraw-Hill Companies, Inc.; 2011.","edition":"12"},{"key":"75_CR22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","volume":"141","author":"M Fang","year":"2004","unstructured":"Fang M, Chang Y, Hylek E, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745\u201352.","journal-title":"Ann Intern Med"},{"key":"75_CR23","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.95.2_Supplement.26S","volume":"95","author":"M Levine","year":"1989","unstructured":"Levine M, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989;95:26S\u201336S.","journal-title":"Chest"},{"key":"75_CR24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/hrt.42.2.128","volume":"42","author":"J Forfar","year":"1979","unstructured":"Forfar J. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J. 1979;42:128\u201332.","journal-title":"Br Heart J"},{"key":"75_CR25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","volume":"118","author":"S Fihn","year":"1993","unstructured":"Fihn S, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118:511\u201320.","journal-title":"Ann Intern Med"},{"issue":"4","key":"75_CR26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/archinte.160.4.470","volume":"160","author":"G Palareti","year":"2000","unstructured":"Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med. 2000;160(4):470\u20138.","journal-title":"Arch Intern Med"},{"key":"75_CR27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","volume":"335","author":"EM Hylek","year":"1996","unstructured":"Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540\u20136.","journal-title":"N Engl J Med"},{"key":"75_CR28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689\u201396.","journal-title":"Circulation"},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archinte.1994.00420130030006","volume":"154","author":"G Albers","year":"1994","unstructured":"Albers G. Three new studies, three remaining questions. Arch Intern Med. 1994;154:1443\u201357.","journal-title":"Arch Intern Med"},{"key":"75_CR30","first-page":"687","volume":"343","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1994","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in Atrial Fibrillation II Study. Lancet. 1994;343:687\u201391.","journal-title":"Lancet"},{"key":"75_CR31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","volume":"167","author":"HD White","year":"2007","unstructured":"White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239\u201345.","journal-title":"Arch Intern Med"},{"issue":"9586","key":"75_CR32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493\u2013503.","journal-title":"Lancet"},{"issue":"11","key":"75_CR33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2009.05.046","volume":"54","author":"D Poli","year":"2009","unstructured":"Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80\u00a0years. J Am Coll Cardiol. 2009;54(11):999\u20131002.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"75_CR34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"key":"75_CR35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"M Patel","year":"2011","unstructured":"Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"75_CR36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"19","key":"75_CR37","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","volume":"364","author":"BN Beasley","year":"2011","unstructured":"Beasley BN, Unger EF, Temple R. Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788\u201390.","journal-title":"N Engl J Med"},{"issue":"8","key":"75_CR38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1592\/phco.31.8.725","volume":"31","author":"JE Hunchuck","year":"2011","unstructured":"Hunchuck JE, Lake JD. Dabigatran for stroke prevention in all patients with atrial fibrillation? Pharmacotherapy. 2011;31(8):725\u20138.","journal-title":"Pharmacotherapy"},{"issue":"21","key":"75_CR39","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363\u201372.","journal-title":"Circulation"},{"issue":"5","key":"75_CR40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"K Uchino","year":"2012","unstructured":"Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397\u2013402.","journal-title":"Arch Intern Med"},{"key":"75_CR41","unstructured":"Quarter Watch. Dabigatran(Pradaxa) and serious bleeding in the elderly. Institute for Safe Medication Practices. 2012. http:\/\/www.ismp.org\/QuarterWatch\/pdfs\/2011Q1.pdf . Accessed 20 Apr 2012."},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765\u201375.","journal-title":"N Engl J Med"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776\u201386.","journal-title":"N Engl J Med"},{"issue":"9632","key":"75_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study. Lancet. 2008;372(9632):31\u20139.","journal-title":"Lancet"},{"issue":"12","key":"75_CR45","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873\u201380.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"75_CR46","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","volume":"24","author":"D Kubitza","year":"2008","unstructured":"Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757\u201365.","journal-title":"Curr Med Res Opin"},{"key":"75_CR47","unstructured":"Clinical Trials.gov. Evaluation of the efficacy and safety of rivaroxaban (BAY59-7939) for the prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00494871 . Accessed 15 Apr 2012."},{"issue":"22","key":"75_CR48","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877\u201385.","journal-title":"Circulation"},{"issue":"6","key":"75_CR49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594\u2013604.","journal-title":"N Engl J Med"},{"issue":"8","key":"75_CR50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","volume":"6","author":"H Buller","year":"2008","unstructured":"Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis: the Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313\u20138.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"75_CR51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806\u201317.","journal-title":"N Engl J Med"},{"key":"75_CR52","unstructured":"Australian Public Assessment Report for Apixaban. Therapeutic Goods Administration. Woden ACT 2606 Australia. http:\/\/www.tga.gov.au\/pdf\/auspar\/auspar-eliquis.pdf . Accessed 17 Apr 2012."},{"issue":"3","key":"75_CR53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","volume":"108","author":"S Mantha","year":"2012","unstructured":"Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476\u201384. doi: 10.1160\/TH12-02-0093 .","journal-title":"Thromb Haemost"},{"issue":"4","key":"75_CR54","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3111\/13696998.2012.680555","volume":"15","author":"S Deitelzweig","year":"2012","unstructured":"Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776\u201385.","journal-title":"J Med Econ"},{"issue":"5","key":"75_CR55","first-page":"681","volume":"41","author":"A Alia","year":"2012","unstructured":"Alia A, Bailey C, Abdelhafiz A. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing. 2012;41(5):681\u20134.","journal-title":"J Med Econ"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0075-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0075-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:50Z","timestamp":1559504510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0075-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}